期刊文献+

食物对奥扎格雷钠口服液人体内吸收的影响 被引量:1

Effects of Food on Absorption of Ozagrel After Oral Administration in Healthy Volunteers
下载PDF
导出
摘要 目的考察食物对奥扎格雷钠口服液药动学影响。方法采用双周期实验设计,选用6名健康志愿者空腹和进食后po200 mg奥扎格雷钠,建立HPLC测定奥扎格雷钠的血药浓度并计算药动学参数,进而对主要药动学参数进行统计分析。结果空腹与进食后的主要药动学参数AUC0-t分别为(3.76±1.15)与(4.13±0.42)mg.h.L-1,AUC0-∞分别为(3.97±1.19)与(4.46±0.61)mg.h.L-1,ρmax分别为(3.61±1.16)与(1.11±0.20)mg.L-1,tmax分别为(0.42±0.13)与(2.75±1.08)h。结论空腹与进食后给药的主要药动学参数ρmax,tmax,AUC0-∞,AUC0-t采用Excel进行成对t检验。ρmax,tmax具有极显著差异(P<0.01)。AUC0-∞,AUC0-t无差异(P>0.05)。 OBJECTIVE To evaluate the effect of food on absorption of ozagrel in 6 healthy volunteers. METHODS In a two period study, 6 healthy male volunteers received a single dose of 200 mg ozagrel either after a fast or after a breakfast. The plasma concentrations of ozagrel were determined by HPLC. The pharmacokinetic parameters of ozagrel were calculated and analyzed with statistical method. RESULTS The main pharmacokinetic parameters of ozagrel after an overnight fast and after a breakfast were as follows: AUC0-t (3.76 ± 1.15) and(4. 13 ±0.42)mg . h^-1. L^-1 , AUC0-∞ (3.97 ± 1.19) and(4. 46 ±0. 61 )mg . h . L^-1 ,pmax(3. 61 ± 1. 16) and (1. 11 ±0.20)mg . L^-1 ,tmax(0.42 ±0. 13)and(2.75 ±1.08)h, respectively. CONCLUSION The results of statistical analysis showed that there was significant difference on pmax tmax ( P 〈 0. 01 ) and there was no significant difference on AUC0-∞ , AUC0-t ( P 〉 0.05) and between after an overnight fast and after a breakfast.
出处 《中国药学杂志》 CAS CSCD 北大核心 2008年第1期57-59,共3页 Chinese Pharmaceutical Journal
关键词 奥扎格雷钠 高效液相色谱法 药动学 ozagrel HPLC pharmacokinetics
  • 相关文献

参考文献3

  • 1SEKI H, KUROMAKI K, TAKEDA S, et al. Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia [ J ] . Hyperten.s Pregnancy, 1999, 18 (2) : 157-164.
  • 2OGISO T, IWAKI M, HARA Y ,et al. Pharmacokinetics of ozagrel and its metabolites after intravenous and oral administrations [J]. Pharm Sci,1997,86(10) :1111-1114.
  • 3ZHENG N X,SATO H, KOBAYSHI F,et al. Rectal absorption of ozagrel from a suppository containing its commercial tablet in healthy human subjects[ J]. Biol Pharm Bull, 1997,20( 3 ) :282- 284.

同被引文献1954

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部